Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation

被引:10
|
作者
Yoon, Jae-Ho [1 ]
Lee, Seok [1 ]
Kim, Hee-Je [1 ]
Lee, Jong-Wook [1 ]
Min, Woo-Sung [1 ]
Chung, Byung Ha [2 ]
Yang, Chul Woo [2 ]
Kim, Yong-Soo [2 ]
Kim, Ji-Il [3 ]
Moon, In Sung [3 ]
Oh, Eun Ji [4 ]
Park, Gyeong-Sin [5 ]
Cho, Seok-Goo [1 ]
机构
[1] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Blood & Marrow Transplantat Ctr, Dept Hematol, Seoul 137701, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Nephrol, Seoul 137701, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea
[4] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Lab Med, Seoul 137701, South Korea
[5] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Pathol, Seoul 137701, South Korea
关键词
hematopoietic stem cell transplantation; kidney transplantation; post-transplant lymphoproliferative disorder; prognosis; SOLID-ORGAN TRANSPLANTATION; PROGNOSTIC-FACTORS; RITUXIMAB; RECIPIENTS; LYMPHOMAS; PTLD; IMMUNOSUPPRESSION; SURVIVAL; DISEASE;
D O I
10.1111/tri.12328
中图分类号
R61 [外科手术学];
学科分类号
摘要
Post-transplant lymphoproliferative disorder (PTLD) is a major complication caused by immune-suppression after transplantation. Survival outcome is known to be poor and the characteristics are not fully understood because of its rare incidence. This single center retrospective study enrolled 41 adult PTLD patients after kidney-transplantation (KT, n=28) and hematopoietic stem cell transplantation (HSCT, n=13) from 1992 to 2012. We compared the characteristics and estimated the survival outcomes according to several factors [age-adjusted-IPI (aaIPI), pathologic subtype, viral status, extranodal manifestation] and added some significant parameters to aaIPI scoring system. Post-HSCT-PTLD patients were younger and showed earlier onset, and viral status was more frequently identified. Ten-year OS of the entire group was 44% but the 10-year OS was not significantly different between post-KT-PTLD and post-HSCT-PTLD (39% vs. 56%, P=0.860). The time onset of PTLD and viral statuses were not meaningful, however, aaIPI, age>50, extranodal manifestation and monomorphic subtype were predictive for OS. We used those factors for PTLD-specific scoring which showed intermediate-risk (HR=7.1, P=0.019) and high-risk (HR=16.5, P=0.001) presented worse OS compared to low-risk subgroup. Although the treatment strategies were heterogenous, this study showed comprehensive PTLD data between KT versus HSCT, and our PTLD-specific scoring might be validated by another larger studies.
引用
收藏
页码:721 / 732
页数:12
相关论文
共 50 条
  • [41] HAPLOIDENTICAL TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS FOR PATIENT WITH POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE
    Vasilyeva, Vera
    Kuzmina, Larisa
    Aleshina, Olga
    Dovydenko, Mariya
    Drokov, Mikhail
    Lukyanova, Irina
    Troitskaya, Vera
    Parovichnikova, Elena
    BONE MARROW TRANSPLANTATION, 2024, 59 : 493 - 494
  • [42] Gastrointestinal tract post-transplant lymphoproliferative disorder after liver transplantation
    Xie, Qin-Fen
    Chen, Ping
    Chen, Xin-Hua
    Liu, Ji-Min
    Lerut, Jan
    Zheng, Shu-Sen
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2017, 16 (05) : 556 - 558
  • [43] RAPIDLY PROGRESSIVE POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER LUNG TRANSPLANTATION
    Olson, M.
    Saeed, A.
    Kodali, M.
    Arjuna, A.
    CHEST, 2022, 161 (06) : 483A - 483A
  • [44] Rituximab in treatment of post-transplant lymphoproliferative disease after allogeneic stem cell transplantation
    Gil, Lidia
    Styczynski, Jan
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2011, 15 (03): : 155 - 158
  • [45] Hematopoietic Stem Cell Transplantation after Posttransplant Lymphoproliferative Disorder
    Kim, Min Joo
    Kim, Inho
    Bae, Hyun-Mi
    Seo, Kyungsuk
    Park, Namjun
    Yoon, Sung-Soo
    Park, Seonyang
    Kim, Byoung Kook
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (05) : 781 - 784
  • [46] A meta-analysis of the outcome of post-transplant lymphoproliferative disorder in adult patients after hematopoietic stem cell transplant
    Kantamneni, L.
    Khanam, R.
    Shah, Z.
    Laek, B.
    Ebad, M.
    Roksana, Z.
    Franco, D.
    Anwer, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S831 - S832
  • [47] Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation
    Asleh, Rabea
    Alnsasra, Hilmi
    Habermann, Thomas M.
    Briasoulis, Alexandros
    Kushwaha, Sudhir S.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [48] Post-transplant lymphoproliferative disorder following non-myeloablative allogeneic stem cell transplantation
    Snyder, MJ
    Stenzel, TT
    Lagoo, AS
    Rizzieri, DA
    Chao, N
    Buckley, PJ
    Gong, JZ
    LABORATORY INVESTIGATION, 2003, 83 (01) : 253A - 253A
  • [49] Post-transplant lymphoproliferative disorder following non-myeloablative allogeneic stem cell transplantation
    Snyder, MJ
    Stenzel, TT
    Lagoo, AS
    Rizzieri, DA
    Chao, N
    Buckley, PJ
    Gong, JZ
    MODERN PATHOLOGY, 2003, 16 (01) : 253A - 253A
  • [50] A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation
    Al Fararjeh, Feras
    Mahmood, Shameem
    Tachtatzis, Phaedra
    Yallop, Deborah
    Devereux, Stephen
    Patten, Piers
    Agrawal, Kosh
    Suddle, Abid
    O'Grady, John
    Heaton, Nigel
    Marcus, Robert
    Kassam, Shireen
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (01) : 98 - 103